Product information and disease descriptionPlace of product in therapy
Disease description
22 evidence topics · 16 sources
Long-term morbidity
No evidence found.
Zanzalintinib (XL092)
Metastatic colorectal cancer
- Manufacturer
- Exelixis
- Regulatory submission
- NDA submitted December 2025
- Launch
- Not announced
- Last updated